Eugenics Lurk in the Shadow of CRISPR
By Robert Pollack,
Science
| 05. 22. 2015
Untitled Document
In calling their perspective “A prudent path forward for genomic engineering and germline gene modification” (3 April, p. 36; published online 19 March), D. Baltimore et al. show at once the size of the problem and the modesty of their response to it. CRISPR-Cas9, invented by the ninth author, Jennifer Doudna, allows the alteration of specific DNA in the mammalian genome. The authors say that “CRISPR-Cas9 technology, as well as other genome engineering methods, can be used to change the DNA in the nuclei of reproductive cells that transmit information from one generation to the next (an organism’s ‘germ line’).” This is a big deal. It means that we can imagine a day when human chromosomes may be modified in the sperm and egg to assure that one or another aspect of a child’s inheritance is designed to order.
This is a huge departure from current understanding, but the authors are remarkably circumspect. They call for the convening of a “globally representative group of developers and users of genome engineering technology and experts in genetics, law, and bioethics...
Related Articles
Since the “CRISPR babies” scandal in 2018, no additional genetically modified babies are known to have been born. Now several techno-enthusiastic billionaires are setting up privately funded companies to genetically edit human embryos, with the explicit intention of creating genetically modified children.
Heritable genome editing remains prohibited by policies in the overwhelming majority of countries that have any relevant policy, and by a binding European treaty. Support for keeping it legally off limits is widespread, including among scientists...
By Ed Cara, Gizmodo | 06.22.2025
In late May, several scientific organizations, including the International Society for Cell and Gene Therapy (ISCT), banded together to call for a 10-year moratorium on using CRISPR and related technologies to pursue human heritable germline editing. The declaration also outlined...
By Isabel van Brugen, Newsweek | 06.05.2025
A U.S.-based biotech company has unveiled a new in vitro fertilization (IVF) option that allows parents to select embryos based on genetic markers tied to health and longevity.
DNA testing and analysis company Nucleus Genomics has announced the world's first...
By Jonathan D. Grinstein, PhD, Inside Precision Medicine | 06.03.2025
On Tuesday, 307 days after he was first admitted to Children’s Hospital of Philadelphia (CHOP), KJ Muldoon went home after being successfully treated with the first personalized CRISPR gene editing therapy. KJ, who was born with a serious and...